Can a simple breath test protect dialysis Patients' brains?

NCT ID NCT05445219

Ongoing Knowledge-focused Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how kidney dialysis affects brain blood flow in 37 adults with chronic kidney failure. Researchers use a special breathing device called RespirAct to measure the brain's response to carbon dioxide before and after dialysis sessions. The goal is to find ways to adjust dialysis to reduce stress on the brain and potentially prevent cognitive decline.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RespirAct device (diagnostic test measuring brain blood flow response to CO2)
What this could lead to: If successful, this could help doctors adjust dialysis to better protect the brain and reduce cognitive decline in kidney patients.
What could go wrong: This is a small, early-stage study with only 37 participants. It is designed to gather information, not to test a treatment, so it may not lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome Cognitive Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC KIDNEY FAILURE

Contacts and locations

Locations

London Health Sciences Centre

London, Ontario, N6A 5W9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.